Sharron Blaylock, MD
Internal Medicine · Bartlesville, OKNPI 1588628978
Payments from drug & device makers
Across 202 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$853
- Novartis$638
- Pfizer$476
- E.r. Squibb & Sons, L.L.C.$223
- Johnson & Johnson$204
- Sun Pharmaceutical Industries Inc.$182
- plus $988 from 18 others
What the payments were for
- Food & beverage$3,46697%
- Education$983%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 55 | $853 |
| Novartis | 31 | $638 |
| Pfizer | 32 | $476 |
| E.r. Squibb & Sons, L.L.C. | 12 | $223 |
| Johnson & Johnson | 11 | $204 |
| Sun Pharmaceutical Industries Inc. | 9 | $182 |
| UCB, Inc. | 10 | $167 |
| Lilly USA, LLC | 8 | $137 |
| Incyte Corporation | 3 | $120 |
| Amgen | 5 | $107 |
| Regeneron Healthcare Solutions, Inc. | 4 | $69 |
| Galderma Laboratories, L.p. | 4 | $58 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $56 |
| Mayne Pharma Commercial LLC | 3 | $49 |
| Sanofi | 2 | $48 |
| LEO Pharma Inc. | 2 | $40 |
| Dermira, Inc. | 1 | $21 |
| Organogenesis Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $18 |
| VYNE Pharmaceuticals Inc. | 1 | $17 |
| Dermavant Sciences, Inc. | 1 | $16 |
| Nabriva Therapeutics, PLC | 1 | $15 |
| Sandoz | 1 | $14 |
| Arcutis Biotherapeutics, Inc. | 1 | $14 |
How this compares
$3,564 in reported general payments places this provider in the 80th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 20 | $434,283 |
| Dupixent SyringeDupilumab | 33 | $131,275 |
| Calcipotriene | 19 | $3,560 |
| Clobetasol Propionate | 29 | $1,543 |
| Fluorouracil | 23 | $1,257 |
| Pentoxifylline | 13 | $763 |
| Ketoconazole | 49 | $747 |
| ValacyclovirValacyclovir Hcl | 17 | $549 |
| Triamcinolone Acetonide | 51 | $471 |
| Doxycycline Hyclate | 13 | $240 |
| MethotrexateMethotrexate Sodium | 14 | $232 |
| Minoxidil | 11 | $167 |
| Hydrocortisone | 17 | $88 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Bartlesville
- Todd ThomasBartlesville$10K
- Al-Ola AbdallahTulsa$10.1M
- Melita TateTulsa$9.1M
- Sagila GeorgeOklahoma City$1.8M
- Ryan MorganOklahoma City$775K
- Renae MayerTulsa$766K
- George FreemanIdabel$742K
- Elise WiesnerNorman$584K
- Steve EgwuonwuLawton$464K
- Mousumi SomTulsa$391K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.